gefitinib has been researched along with Bladder Cancer in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (54.55) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CT; Chen, JN; Cheng, L; He, YZ; Li, QY; Li, T; Liu, G; Qin, TS; Sun, YX; Wei, Y; Yao, D; Zhang, GJ | 1 |
| Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J | 1 |
| Darko, KO; Deng, J; He, C; Huang, Y; Peng, M; Su, Q; Tao, T; Yang, X; Zhou, S | 1 |
| Deng, J; Peng, J; Peng, M; Wang, Z; Xiao, D; Yang, X; Zhou, S | 1 |
| Aldousari, S; Chevalier, S; Kassouf, W; Mansure, JJ; Nassim, R; Rocha, J; Szymanski, K | 1 |
| He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Luo, Z; Nitin, N; Samadzadeh, KM | 1 |
| Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Adam, L; Bar-Eli, M; Black, PC; Brown, GA; Dinney, CP; Fisher, MB; Gallagher, D; Inamoto, T; Kassouf, W; Luongo, T; McConkey, DJ | 1 |
| Bemis, LT; Flaig, TW; Li, Y; McCoach, C; Raben, D; Su, LJ; Varella-Garcia, M | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Bode, AM; Grubbs, CJ; Juliana, MM; Lu, Y; Lubet, RA; Steele, VE; Townsend, R; Verney, ZM; You, M | 1 |
| Grubbs, CJ; James, M; Liu, P; Lu, Y; Lubet, RA; Van den Bergh, F; Wen, W; You, M; Zellmer, V | 1 |
| Kim, JJ | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK; Symonds, RP | 1 |
| Lazarowicz, HP; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Davies, BR; Dominguez-Escrig, JL; Kelly, JD; King, SM; Neal, DE | 1 |
| Clarke, NW; Hendry, JH; Maddineni, SB; Margison, GP; Sangar, VK | 1 |
| Adam, L; Bar-Eli, M; Brown, G; Diehl, AJ; Dinney, CP; Kassouf, W; McConkey, DJ | 1 |
| Akaza, H; Hattori, K; Iida, K; Joraku, A; Oyasu, R; Tsukamoto, S | 1 |
| Adam, L; Brown, G; Dinney, CP; Kassouf, W; Luongo, T | 1 |
| Memon, AA; Munk, M; Nexo, E; Sorensen, BS | 1 |
| Memon, AA; Nexo, E; Sorensen, SB | 1 |
| Nexo, E; Ornskov, D; Sorensen, BS | 1 |
| Adam, L; Bar-Eli, M; Black, P; Brown, G; Dinney, CP; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Adam, L; Bar-Eli, M; Dinney, CP; Lashinger, L; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Foster, PA; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Colquhoun, AJ; Kriajevska, M; Mchugh, LA; Mellon, JK; Tulchinsky, E | 1 |
4 review(s) available for gefitinib and Bladder Cancer
| Article | Year |
|---|---|
Novel application of metformin combined with targeted drugs on anticancer treatment.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Gefitinib; Humans; Metformin; Molecular Targeted Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Recent advances in treatment of advanced urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Doxorubicin; Female; Gefitinib; Humans; Immunotherapy; Male; Methotrexate; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quality Improvement; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Methotrexate; Muscle Neoplasms; Neoadjuvant Therapy; Oncogene Proteins v-erbB; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Urinary Bladder Neoplasms; Vinblastine | 2004 |
1 trial(s) available for gefitinib and Bladder Cancer
| Article | Year |
|---|---|
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
28 other study(ies) available for gefitinib and Bladder Cancer
| Article | Year |
|---|---|
Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Glutathione Peroxidase; Humans; Intracellular Space; Molecular Docking Simulation; Protein Conformation; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship; Urea; Urinary Bladder Neoplasms | 2020 |
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Phenformin; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Topics: Animals; Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; PPAR gamma; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, p53; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gefitinib; Humans; Optical Imaging; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Topics: Analysis of Variance; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2008 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Piperidines; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2009 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Butylhydroxybutylnitrosamine; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Models, Biological; Quinazolines; Rats; Signal Transduction; Urinary Bladder Neoplasms | 2011 |
Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Urinary Bladder Neoplasms | 2012 |
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
Topics: Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protease Inhibitors; Quinazolines; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Growth Processes; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Urinary Bladder Neoplasms | 2005 |
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cyclooxygenase Inhibitors; Gefitinib; Male; Meloxicam; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Thiazines; Thiazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Administration Schedule; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Quinazolines; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; ErbB Receptors; Etoposide; Gefitinib; Humans; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Topics: Biomarkers; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Multigene Family; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Urinary Bladder Neoplasms | 2006 |
Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
Topics: Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Ligands; Quinazolines; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Urinary Bladder Neoplasms | 2006 |
Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; G1 Phase; Gefitinib; Humans; Mesoderm; Mice; Quinazolines; S Phase; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2007 |
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; X-Linked Inhibitor of Apoptosis Protein | 2007 |
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Early Growth Response Protein 1; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2007 |
Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |